Skip to main content
Fig. 1 | The Journal of Headache and Pain

Fig. 1

From: Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study

Fig. 1

Completer analysis showing MIDAS total score overall and for patients who completed a maximum of 3, 6, 9, or 12 months of study for a) Lasmiditan 100 mg and b) Lasmiditan 200 mg. Abbreviations: Mo. = month. Note that N within completer subgroups remained nearly constant (within 2 patients) across relevant timepoints

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us